請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7395
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賴飛羆 | |
dc.contributor.author | Fong-Ci Lin | en |
dc.contributor.author | 林峰祺 | zh_TW |
dc.date.accessioned | 2021-05-19T17:42:48Z | - |
dc.date.available | 2024-01-30 | |
dc.date.available | 2021-05-19T17:42:48Z | - |
dc.date.copyright | 2019-01-30 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-01-30 | |
dc.identifier.citation | 1. Coloma, P.M., et al., Postmarketing safety surveillance. Drug safety, 2013. 36(3): p. 183-197.
2. Heiat, A., C.P. Gross, and H.M. Krumholz, Representation of the elderly, women, and minorities in heart failure clinical trials. Archives of internal medicine, 2002. 162(15). 3. Papanikolaou, P.N., G.D. Christidi, and J.P. Ioannidis, Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. Canadian medical association journal, 2006. 174(5): p. 635-641. 4. Zarin, D.A., J.L. Young, and J.C. West, Challenges to evidence-based medicine. Social psychiatry and psychiatric epidemiology, 2005. 40(1): p. 27-35. 5. Linder, J.A., et al., Electronic health record use and the quality of ambulatory care in the United States. Archives of internal medicine, 2007. 167(13): p. 1400-1405. 6. Classen, D.C. and D.W. Bates, Finding the meaning in meaningful use. 2011, Mass Medical Soc. 7. Waitman, L.R., et al., The Greater Plains Collaborative: a PCORnet Clinical Research Data Network. Journal of the American Medical Informatics Association, 2014. 21(4): p. 637-641. 8. Fleurence, R.L., et al., Launching PCORnet, a national patient-centered clinical research network. Journal of the American Medical Informatics Association, 2014. 21(4): p. 578-582. 9. Hripcsak, G., et al., Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Studies in health technology and informatics, 2015. 216: p. 574. 10. Natter, M.D., et al., An i2b2-based, generalizable, open source, self-scaling chronic disease registry. Journal of the American Medical Informatics Association, 2013. 20(1): p. 172-179. 11. Obeid, J.S., et al., Procurement of shared data instruments for research electronic data capture (REDCap). Journal of biomedical informatics, 2013. 46(2): p. 259-265. 12. Alghabban, A., Dictionary of pharmacovigilance. 2004: Pharmaceutical Press. 13. Fukuoka, Y., et al., Real-time social support through a mobile virtual community to improve healthy behavior in overweight and sedentary adults: a focus group analysis. Journal of medical Internet research, 2011. 13(3). 14. Sànchez-Riera, L., et al., The global burden attributable to low bone mineral density. Annals of the rheumatic diseases, 2014: p. annrheumdis-2013-204320. 15. Iburg, K.M., Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 2017. 390(10100): p. 1345-1422. 16. Burge, R., et al., Incidence and economic burden of osteoporosis‐related fractures in the United States, 2005–2025. Journal of bone and mineral research, 2007. 22(3): p. 465-475. 17. Cosman, F., et al., Clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis international, 2014. 25(10): p. 2359-2381. 18. Compston, J., et al., Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas, 2009. 62(2): p. 105-108. 19. Watts, N., et al., American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocrine Practice, 2010. 16(Supplement 3): p. 1-37. 20. Orimo, H., et al., Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. Archives of osteoporosis, 2012. 7(1-2): p. 3-20. 21. Hwang, J.-S., et al., Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary. Journal of bone and mineral metabolism, 2014. 32(1): p. 10-16. 22. Formiga, F., et al., Failure to treat osteoporosis and the risk of subsequent fractures in elderly patients with previous hip fracture: a five-year retrospective study. Aging clinical and experimental research, 2005. 17(2): p. 96-99. 23. Rabenda, V., et al., Low incidence of anti-osteoporosis treatment after hip fracture. JBJS, 2008. 90(10): p. 2142-2148. 24. Wilk, A., et al., Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA. Osteoporosis International, 2014. 25(12): p. 2777-2786. 25. Klop, C., et al., Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010. Osteoporosis International, 2015. 26(7): p. 1919-1928. 26. Chiang, C.-E., et al., 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. Journal of the Formosan Medical Association, 2016. 115(11): p. 893-952. 27. Chugh, S.S., et al., Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation, 2013: p. CIRCULATIONAHA. 113.005119. 28. Lip, G.Y., et al., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest, 2010. 137(2): p. 263-272. 29. January, C., et al., AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online ahead of print March 28, 2014]. Circulation. doi, 2014. 10. 30. Lindquist, M. and I.R. Edwards, The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. The Journal of rheumatology, 2001. 28(5): p. 1180-1187. 31. Härmark, L. and K. van Grootheest, Web-based intensive monitoring: from passive to active drug surveillance. Expert opinion on drug safety, 2012. 11(1): p. 45-51. 32. Behrman, R.E., et al., Developing the Sentinel System—a national resource for evidence development. New England Journal of Medicine, 2011. 364(6): p. 498-499. 33. Coloma, P.M., et al., A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug safety, 2013. 36(1): p. 13-23. 34. Coloma, P.M., et al., Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiology and drug safety, 2012. 21(6): p. 611-621. 35. Härmark, L. and A. Van Grootheest, Pharmacovigilance: methods, recent developments and future perspectives. European journal of clinical pharmacology, 2008. 64(8): p. 743-752. 36. Keyes, C.L., Promoting and protecting mental health as flourishing: A complementary strategy for improving national mental health. American psychologist, 2007. 62(2): p. 95. 37. Krumholz, H.M., et al., What have we learnt from Vioxx? Bmj, 2007. 334(7585): p. 120-123. 38. Aronson, J.K., M. Hauben, and A. Bate, Defining ‘surveillance’in drug safety. Drug safety, 2012. 35(5): p. 347-357. 39. Du, W., et al., Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai. Can J Clin Pharmacol, 2007. 14(1): p. e40-e44. 40. collaborators, A., et al., The Asian Pharmacoepidemiology Network (AsPEN): promoting multi‐national collaboration for pharmacoepidemiologic research in Asia. pharmacoepidemiology and drug safety, 2013. 22(7): p. 700-704. 41. Pratt, N., et al. A Practical Guide to Implementing Sequence Symmetry Analysis; a Tool for Conducting Studies in the Asian Pharmacoepidemiology Network (AsPEN). in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2017. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA. 42. Coloma, P.M., et al., Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR Project. Pharmacoepidemiology and drug safety, 2011. 20(1): p. 1-11. 43. Hauben, M. and J.K. Aronson, Defining ‘signal’and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug safety, 2009. 32(2): p. 99-110. 44. Szarfman, A., S.G. Machado, and R.T. O’neill, Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Safety, 2002. 25(6): p. 381-392. 45. Brown, J., et al., Blueprint for a distributed research network to conduct population studies and safety surveillance. Effective Health Care Program Research Reports, 2010(27). 46. Brown, J.S., et al., Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Medical care, 2010. 48(6): p. S45-S51. 47. Ball, R., et al., The FDA's sentinel initiative—a comprehensive approach to medical product surveillance. Clinical Pharmacology & Therapeutics, 2016. 99(3): p. 265-268. 48. Lowe, H.J., et al. STRIDE–An integrated standards-based translational research informatics platform. in AMIA Annual Symposium Proceedings. 2009. American Medical Informatics Association. 49. Pattanayak, C.W., D.B. Rubin, and E.R. Zell, Propensity score methods for creating covariate balance in observational studies. Revista Española de Cardiología (English Edition), 2011. 64(10): p. 897-903. 50. Austin, P.C., An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate behavioral research, 2011. 46(3): p. 399-424. 51. Rosenbaum, P.R. and D.B. Rubin, The central role of the propensity score in observational studies for causal effects. Biometrika, 1983. 70(1): p. 41-55. 52. Flury, B.K. and H. Riedwyl, Standard distance in univariate and multivariate analysis. The American Statistician, 1986. 40(3): p. 249-251. 53. Gallin, J.I. and F.P. Ognibene, Principles and practice of clinical research. 2012: Academic Press. 54. Kartsonaki, C., Survival analysis. Diagnostic Histopathology, 2016. 22(7): p. 263-270. 55. Efron, B., Logistic regression, survival analysis, and the Kaplan-Meier curve. Journal of the American statistical Association, 1988. 83(402): p. 414-425. 56. Hosmer, D.W., S. Lemeshow, and S. May, Applied survival analysis. 2011: Wiley Blackwell. 57. Cox, D.R., Analysis of survival data. 2018: Routledge. 58. Austin, P.C., The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Medical Decision Making, 2009. 29(6): p. 661-677. 59. Austin, P.C., A comparison of 12 algorithms for matching on the propensity score. Statistics in medicine, 2014. 33(6): p. 1057-1069. 60. Ten Have, T.R., et al., Intent-to-treat vs. non-intent-to-treat analyses under treatment non-adherence in mental health randomized trials. Psychiatric annals, 2008. 38(12). 61. Singh, S. and Y.K. Loke, Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials, 2012. 13(1): p. 138. 62. Liao, J.M., et al., Annals understanding clinical research: intention-to-treat analysis. Annals of internal medicine, 2017. 166(9): p. 662-664. 63. McNamee, R., Intention to treat, per protocol, as treated and instrumental variable estimators given non‐compliance and effect heterogeneity. Statistics in medicine, 2009. 28(21): p. 2639-2652. 64. Therneau, T.M. and P.M. Grambsch, Modeling survival data: extending the Cox model. 2013: Springer Science & Business Media. 65. Wickham, H., ggplot2: elegant graphics for data analysis. 2016: Springer. 66. Harrell, F.E., Cox proportional hazards regression model, in Regression modeling strategies. 2015, Springer. p. 475-519. 67. Ansell, J., et al., Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2008. 133(6): p. 160S-198S. 68. Members, A.T.F., et al., 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. European heart journal, 2012. 33(21): p. 2719-2747. 69. Hylek, E.M., et al., Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation, 2007. 115(21): p. 2689-2696. 70. Hanley, C.M. and P.R. Kowey, Are the novel anticoagulants better than warfarin for patients with atrial fibrillation? Journal of thoracic disease, 2015. 7(2): p. 165. 71. Kirchhooff, P., et al., ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS 2016. Europace, 2016. 18(11): p. 1609-78. 72. Patel, M.R., et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine, 2011. 365(10): p. 883-891. 73. Granger, C.B., et al., Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 2011. 365(11): p. 981-992. 74. Connolly, S.J., et al., Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 2009. 361(12): p. 1139-1151. 75. Yoo, S., et al., Electronically implemented clinical indicators based on a data warehouse in a tertiary hospital: its clinical benefit and effectiveness. International journal of medical informatics, 2014. 83(7): p. 507-516. 76. Martin, G.S., et al., The epidemiology of sepsis in the United States from 1979 through 2000. New England Journal of Medicine, 2003. 348(16): p. 1546-1554. 77. Angus, D.C., et al., Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical care medicine, 2001. 29(7): p. 1303-1310. 78. Wang, H.E., et al., National estimates of severe sepsis in United States emergency departments. Critical care medicine, 2007. 35(8): p. 1928-1936. 79. Dombrovskiy, V.Y., et al., Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Critical care medicine, 2007. 35(5): p. 1244-1250. 80. Hsieh, C.-Y., et al., Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. Journal of the Formosan Medical Association, 2015. 114(3): p. 254-259. 81. Usui, M., et al., Extraction and Standardization of Patient Complaints from Electronic Medication Histories for Pharmacovigilance: Natural Language Processing Analysis in Japanese. JMIR medical informatics, 2018. 6(3): p. e11021. 82. Guetterman, T.C., et al., Augmenting Qualitative Text Analysis with Natural Language Processing: Methodological Study. Journal of medical Internet research, 2018. 20(6). 83. Duane, S., et al., Using Mobile Phones to Collect Patient Data: Lessons Learned From the SIMPle Study. JMIR research protocols, 2017. 6(4). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7395 | - |
dc.description.abstract | 儘管隨機對照試驗被認為是新藥批准的標準研究方法,但仍無法檢測到所有不良藥物事件。由於許多嚴重的藥物不良反應,許多藥物在市場批准後仍被撤回。因此,藥品核可後,病人的藥品使用安全性和有效性的持續性監測和評估是非常重要的。
為了了解病人群對藥品使用安全性、有效性、即時性與持續性監測,並提供臨床效果研究資料的取得與應用。我們開發了基於網路服務的臨床安全監測系統,此系統基於台大醫院的醫療整合資料庫,實作了一系列的以電子病歷資料的擷取自動化流程,方便醫療研究人員在系統介面設計自己的研究參數,指定藥品安全監測分析方法,進而透過此平台產生監測之報告。為了驗證系統的結果,我們在該研究中建立了兩個臨床應用。我們研究了骨質疏鬆性骨折患者的醫療指引的順從性。 第二個應用我們調查了NOACs和warfarin在非瓣膜性心房顫動患者中的有效性和安全性的差異。 根據醫療指引我們透過系統檢索了2010至2014年間,識別出2,193新罹患骨質疏鬆性骨折的病人,藉由系統的進一步的篩選功能,共找出了1,808位病人(82.44%, 1,808/2,193)在三個月內有回到臺大醫院繼續接受治療,其中僅有464位病人 (21.16%, 464/2,193) 在一年內有根據醫療指引服用抗骨質疏鬆的藥物。 我們在2010年至2015年期間識別出2,357名的病患,為新使用口服抗凝劑的非瓣膜性房顫患者,並進一步分析了缺血性中風作為臨床療效的比較與顱內出血作為安全性的比較。在缺血性中風的結果中,與服用warfarin病患相比,NOACs用戶在調整意向治療(ITT)分析中,罹患缺血性中風的風險顯著降低(P = 0.01)。在治療(AT)分析中具有風險則沒有差異(P = 0.12)。 在顱內出血安全性比較,NOACs病患在ITT分析為(P = 0.68)和AT分析為(P = 0.15)其風險並沒有差異。 由此可知,臨床安全監測系統提供了可參數化的設計,研究人員可以專注於解決臨床研究問題,此系統則可以進行資料自動擷取,並進一步產生監測報告。此系統可以加速臨床研究的流程,並提供決策者基於電子病歷的證據,以協助醫院或醫事人員進行決策。 | zh_TW |
dc.description.abstract | Although the randomized control trial is considered as a gold standard research approach for the new drug approval, such a trial may fail to detect all the adverse drug events. Numerous drugs were still withdrawn after the market approval because of the unexpected severe adverse drug reaction. Therefore, it is a critical issue to establish a well-design effective and convenient active post-marketing drug surveillance system, which is the process of continuous monitoring and evaluation of the drug safety and effectiveness after their listing.
We implemented a web-based clinical surveillance system, the National Taiwan University Hospital Clinical Surveillance System (NCSS) that can integrate the workflow of cohort identification to accelerate the survey process of disease and medication prescription patterns and provide a high reusability infrastructure for a computerized workflow to capture relevant longitudinal clinical data and make those data repositories reusable. In order to valid the result of NCSS, we established two clinical applications in the study. The first application of the NCSS, we looked at the identification of osteoporotic fracture patients and their utilization in pharmacological therapy. The second application, we investigated the difference of effectiveness and safety between NOACs and warfarin in the patients with non-valvular atrial fibrillation. By applying the NCSS, we efficiently identified 2,193 patients who were newly diagnosed with a hip or vertebral fracture between 2010 and 2014 at NTUH. By adopting the filter function, we identified 1808 (82.44%, 1808/2,193) patients who continued their follow-up at NTUH, and 464 (21.16%, 464/2,193) patients who have prescribed anti-osteoporosis medications (AOMs), within 3 and 12 months post the index date of their fracture, respectively. On average, only 35% of female and 28% of male osteoporotic fracture patients initiated AOM therapy to prevent a subsequent fracture. More effort is warranted to improve the quality of care with these patients. We demonstrated the practical example of investigating the difference of effectiveness and safety between NOACs and warfarin in the patients with non-valvular atrial fibrillation at NCSS. We efficiently identified 2,357 non-valvular AF patients with newly prescribed oral anticoagulant between 2010 and 2015 and further developed one main cohort and two sub-cohorts for measuring ischemic stroke as clinical effectiveness outcome and intracranial hemorrhage as safety outcome separately. In ischemic stroke, compared to warfarin users, NOACs users have a significantly lower risk of ischemic stroke after adjusting for age, sex, comorbidity and co-medication in intention-to-treat (ITT) analysis (P = 0.01) but have a comparable risk in as-treated (AT) analysis (P = 0.12) after the 2-year follow-up. In intracranial hemorrhage, NOACs users have a comparable risk of ICH both in ITT (P = 0.68) and AT analysis (P = 0.15). The NCSS systems can integrate the workflow of cohort identification to accelerate the survey process of clinically relevant problems and provide decision support in the daily practice of clinical physicians, thereby making the benefit of evidence-based medicine a reality. | en |
dc.description.provenance | Made available in DSpace on 2021-05-19T17:42:48Z (GMT). No. of bitstreams: 1 ntu-108-D02945017-1.pdf: 3834730 bytes, checksum: 564c9ca84587237afabfcbee750a2665 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 中文摘要 i
ABSTRACT iii CONTENTS v LIST OF FIGURES viii LIST OF TABLES x Chapter 1. Introduction 1 1.1 Background and Significance 1 1.2 Clinical Surveillance Program 2 1.3 Two Clinical Applications of the NCSS 3 1.4 The Aim of this Study 6 Chapter 2. Literature Review 7 2.1 Introduction to Clinical Drug Surveillance System 7 2.2 The Propensity Score Matching 11 2.3 Survival Analysis 13 Chapter 3. Clinical Surveillance System 20 3.1 Data Warehouse 20 3.2 Workflow of NCSS 21 3.2.1 Stage 1. Build a Template of Clinical Orders 23 3.2.2 Stage 2. Patient Identification 23 3.2.3 Stage 3. Cohort Tree Analysis 26 3.3 The Clinical Application of the NCSS in the Identification of Osteoporotic Fracture Patients 28 3.3.1 Study Participants 28 3.4 Investigating the Difference of Effectiveness and Safety between Non-vitamin K Antagonist Oral Anticoagulants and Warfarin in the Patients with Non-valvular Atrial Fibrillation 30 3.4.1 Study Participants 31 3.4.2 Data Definition and Outcome Definition 32 3.4.3 Baseline Characteristics and Covariates 35 3.4.4 Statistical Analysis Method 37 Chapter 4. Results 39 4.1 The Clinical Application of the NCSS in the Identification of Osteoporotic Fracture Patients 39 4.2 Investigating the Clinical Effectiveness and Safety between Non-vitamin K Antagonist Oral Anticoagulants and Warfarin in Patients with Non-valvular Atrial Fibrillation 44 Chapter 5. Discussion 55 5.1 Preliminary Findings 55 5.2 Comparison with Prior Work 56 5.3 Limitations 61 5.4 Future Work 62 Chapter 6. Conclusion 63 REFERENCES 64 APPENDIX 70 | |
dc.language.iso | en | |
dc.title | 臨床療效及安全性之主動監測系統 | zh_TW |
dc.title | Active Surveillance System for
Clinical Effectiveness and Safety | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 歐陽彥正,趙坤茂,黃織芬,鐘玉芳,蕭斐元 | |
dc.subject.keyword | 臨床監測系統,骨質疏鬆性骨折,藥品安全,抗凝血劑, | zh_TW |
dc.subject.keyword | Clinical Surveillance System,Osteoporotic Fractures,Pharmacovigilance,Drug Safety,Anticoagulants, | en |
dc.relation.page | 91 | |
dc.identifier.doi | 10.6342/NTU201900301 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2019-01-30 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 生醫電子與資訊學研究所 | zh_TW |
dc.date.embargo-lift | 2024-01-30 | - |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf | 3.74 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。